US-based Breckenridge Pharmaceutical Inc, a subsidiary of Towa Pharmaceutical, announced on Tuesday that it has been granted final approval from the United States Food and Drug Administration (FDA) for its Everolimus Tablets (generic for Zortress).

The product was produced in partnership with Natco Pharma Limited. The company is planning to launch Everolimus Tablets in 0.25mg, 0.5mg and 0.75mg strengths during the third quarter of 2021 in a blister card packaging configuration.

According to industry sales data, Zortress and its therapeutic equivalents generated USD162 million in annual sales for the twelve months ending March 2021.